-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
Avalo Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from 2013 to 2023.
- Avalo Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending September 30, 2024 was $35.9M.
- Avalo Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending September 30, 2024 was $54.9M.
- Avalo Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was -$4.18M, a 0.26% increase from 2022.
- Avalo Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was -$4.19M, a 73.8% decline from 2021.
- Avalo Therapeutics, Inc. annual Nonoperating Income (Expense) for 2021 was -$2.41M, a 143% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Growth (%)